These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 30187872

  • 1. [Efficacy and metabolic safety of long-term treatment with ethinyl oestradiol/cyproterone and desogestrel/ethinyl oestradiol tablets in women with polycystic ovary syndrome].
    Zhang J, Su M, Xu L, Yang Z, Yin W, Nie Y, Qiao X, Cheng R, Ma Y.
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jul 30; 38(8):917-922. PubMed ID: 30187872
    [Abstract] [Full Text] [Related]

  • 2. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR.
    Fertil Steril; 2010 Oct 30; 94(5):1793-8. PubMed ID: 19931080
    [Abstract] [Full Text] [Related]

  • 3. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.
    Armstrong VL, Wiggam MI, Ennis CN, Sheridan B, Traub AI, Atkinson AB, Bell PM.
    QJM; 2001 Jan 30; 94(1):31-7. PubMed ID: 11161134
    [Abstract] [Full Text] [Related]

  • 4. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome.
    Mhao NS, Al-Hilli AS, Hadi NR, Jamil DA, Al-Aubaidy HA.
    Diabetes Metab Syndr; 2016 Jan 30; 10(1 Suppl 1):S95-8. PubMed ID: 26703220
    [Abstract] [Full Text] [Related]

  • 5. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS.
    J Clin Endocrinol Metab; 2003 Jan 30; 88(1):148-56. PubMed ID: 12519844
    [Abstract] [Full Text] [Related]

  • 6. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
    Leelaphiwat S, Jongwutiwes T, Lertvikool S, Tabcharoen C, Sukprasert M, Rattanasiri S, Weerakiet S.
    J Obstet Gynaecol Res; 2015 Mar 30; 41(3):402-10. PubMed ID: 25319761
    [Abstract] [Full Text] [Related]

  • 7. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS.
    J Clin Endocrinol Metab; 2000 Sep 30; 85(9):3161-8. PubMed ID: 10999803
    [Abstract] [Full Text] [Related]

  • 8. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul 30; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 9. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
    Kabil Kucur S, Gozukara I, Aksoy A, Uludag EU, Keskin H, Kamalak Z, Carlioglu A.
    Blood Coagul Fibrinolysis; 2015 Dec 30; 26(8):862-5. PubMed ID: 25402193
    [Abstract] [Full Text] [Related]

  • 10. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.
    Elter K, Imir G, Durmusoglu F.
    Hum Reprod; 2002 Jul 30; 17(7):1729-37. PubMed ID: 12093831
    [Abstract] [Full Text] [Related]

  • 11. The influence of combined cyproterone acetate-ethinyl oestradiol therapy on serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women.
    Frölich M, Lachinsky N, Moolenaar AJ.
    Acta Endocrinol (Copenh); 1977 Feb 30; 84(2):333-42. PubMed ID: 138326
    [Abstract] [Full Text] [Related]

  • 12. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
    Falsetti L, Pasinetti E.
    Acta Obstet Gynecol Scand; 1995 Jan 30; 74(1):56-60. PubMed ID: 7856434
    [Abstract] [Full Text] [Related]

  • 13. Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial.
    Sahu A, Tripathy P, Mohanty J, Nagy A.
    J Gynecol Obstet Hum Reprod; 2019 May 30; 48(5):335-339. PubMed ID: 30316907
    [Abstract] [Full Text] [Related]

  • 14. Exploring the significance of sex hormone-binding globulin examination in the treament of women with polycystic ovarian syndrome (PCOS).
    Lin XF, Wu RR, Du J, Liao YC, Du Y, Ye Y, Wang Y, Zhang XB, Wu C, Chen A.
    Clin Exp Obstet Gynecol; 2015 May 30; 42(3):315-20. PubMed ID: 26152001
    [Abstract] [Full Text] [Related]

  • 15. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.
    Mastorakos G, Koliopoulos C, Creatsas G.
    Fertil Steril; 2002 May 30; 77(5):919-27. PubMed ID: 12009344
    [Abstract] [Full Text] [Related]

  • 16. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
    Song J, Ruan X, Gu M, Wang L, Wang H, Mueck AO.
    Gynecol Endocrinol; 2018 May 30; 34(5):413-417. PubMed ID: 29172796
    [Abstract] [Full Text] [Related]

  • 17. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel.
    Cagnacci A, Paoletti AM, Renzi A, Orrù M, Pilloni M, Melis GB, Volpe A.
    J Clin Endocrinol Metab; 2003 Aug 30; 88(8):3621-5. PubMed ID: 12915645
    [Abstract] [Full Text] [Related]

  • 18. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
    Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC.
    Contraception; 2010 Aug 30; 82(2):139-46. PubMed ID: 20654754
    [Abstract] [Full Text] [Related]

  • 19. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
    Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ.
    Fertil Steril; 2010 Jan 30; 93(1):184-91. PubMed ID: 19019358
    [Abstract] [Full Text] [Related]

  • 20. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
    Ye BL, Yang HY, Zhao JZ, Lin JJ, Lin WQ.
    Zhonghua Fu Chan Ke Za Zhi; 2003 Dec 30; 38(12):745-8. PubMed ID: 14728846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.